0000000000605873

AUTHOR

Bernd Gerber

showing 7 related works from this author

Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study…

2013

Abstract Background We evaluated the pathological complete response (pCR) rate after neoadjuvant epirubicin, (E) cyclophosphamide (C) and docetaxel containing chemotherapy with and without the addition of bevacizumab in patients with triple-negative breast cancer (TNBC). Patients and methods Patients with untreated cT1c-4d TNBC represented a stratified subset of the 1948 participants of the HER2-negative part of the GeparQuinto trial. Patients were randomized to receive four cycles EC (90/600 mg/m2; q3w) followed by four cycles docetaxel (100 mg/m2; q3w) each with or without bevacizumab (15 mg/kg; q3w) added to chemotherapy. Results TNBC patients were randomized to chemotherapy without (n =…

OncologyAdultmedicine.medical_specialtyBevacizumabCyclophosphamideAnthracyclinePaclitaxelmedicine.medical_treatmentTriple Negative Breast NeoplasmsAntibodies Monoclonal HumanizedYoung AdultBreast cancerInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAnthracyclinesEverolimusCyclophosphamideAgedEpirubicinUltrasonographySirolimusChemotherapyTaxanebusiness.industryCarcinoma Ductal BreastHematologyMiddle Agedmedicine.diseaseNeoadjuvant TherapyTumor BurdenBevacizumabTreatment OutcomeOncologyDocetaxelChemotherapy AdjuvantMultivariate AnalysisFemalebusinessmedicine.drugEpirubicinAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

AGO Recommendations for the Surgical Therapy of the Axilla After Neoadjuvant Chemotherapy: 2021 Update

2021

Geburtshilfe und Frauenheilkunde 81(10), 1112-1120 (2021). doi:10.1055/a-1499-8431

medicine.medical_specialtyAxillary lymph nodesBreast surgerymedicine.medical_treatmentMammakarzinomBreast cancerbreast cancerMaternity and MidwiferyAdjuvant therapymedicineddc:610GebFra ScienceStage (cooking)Sentinel-Lymphknoten-Entfernungtargeted axillary dissectionsentinel LNEneoadjuvante Chemotherapiebusiness.industryObstetrics and Gynecologymedicine.diseaseRadiation therapyDissectionAxillamedicine.anatomical_structuregezielte axilläre DissektionRadiologybusinessRecommendation/Empfehlungneoadjuvant chemotherapy
researchProduct

Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032…

2018

Geburtshilfe und Frauenheilkunde 78(11), 1056-1088 (2018). doi:10.1055/a-0646-4630

medicine.medical_specialtyAdvanced breastPsychological interventionGuideline/LeitlinieSystemic therapymetastasiertes Mammakarzinomprimary breast cancer03 medical and health sciences0302 clinical medicineBreast cancerbreast cancerMaternity and MidwiferyBrustkrebsMedicineprimäres Mammakarzinom030212 general & internal medicineGebFra ScienceIntensive care medicineLeitlinietherapybusiness.industryTumor biologyObstetrics and GynecologyCancerGuidelinemedicine.diseaseMetastatic breast cancerddc:030220 oncology & carcinogenesismetastatic breast cancerbusinessTherapieguideline
researchProduct

AGO Algorithms for the Treatment of Breast Cancer: Update 2021

2021

Geburtshilfe und Frauenheilkunde 81(10), 1101-1111 (2021). doi:10.1055/a-1519-7089

Evidence-based practicePerformance statusbusiness.industryObstetrics and GynecologyTreatment optionsRecommendationmedicine.diseasetherapy algorithmsPatient preferenceMetastatic breast cancerevidence-based treatmentBreast cancerevidenzbasierte TherapieMaternity and Midwiferybreast cancer guidelinesmedicineTreatment decision makingGebFra ScienceBehandlungsalgorithmenbusinessAlgorithmBrustkrebs-Leitlinien
researchProduct

Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032…

2018

62. Kongress der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe, DGGG'18, Berlin, Germany, 31 Oct 2018 - 3 Nov 2018; Geburtshilfe und Frauenheilkunde 78(10), 927-948 (2018). doi:10.1055/a-0646-4522 special issue: "62. Kongress der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe, DGGG'18, Berlin, 31.10 – 03.11.2018 : Frauenheilkunde im Fokus: wissenschaftlich fundiert und der Qualität verpflichtet"

medicine.medical_specialtydiagnosisPsychological interventionComputed tomographyDiseaseGuideline/LeitlinieMammakarzinom03 medical and health sciencesbreast cancerDiagnostik0302 clinical medicineBreast cancerMaternity and Midwiferyfollow-upmedicineMammographyMedical physicsGebFra Science030212 general & internal medicinemedicine.diagnostic_testbusiness.industryscreeningObstetrics and GynecologyCancerGuidelinemedicine.diseaseddc:030220 oncology & carcinogenesisFrüherkennungRichtlinieNachsorgebusinessguidelineSystematic searchGeburtshilfe und Frauenheilkunde
researchProduct

Sorafenib (SOR) plus docetaxel (DOC) as first-line therapy in patients with HER2-negative metastatic breast cancer (MBC): A randomized, placebo-contr…

2014

1072 Background: Anti-angiogenic therapy with the monoclonal anti-VEGF antibody Bevacizumab (Bev) in combination with chemotherapy increases overall response rates (ORR) and progression free surviv...

OncologySorafenibCancer Researchmedicine.medical_specialtyChemotherapyBevacizumabbusiness.industrymedicine.medical_treatmentPharmacologyPlacebomedicine.diseaseMetastatic breast cancerOncologyDocetaxelInternal medicineMonoclonalMedicineIn patientbusinessmedicine.drugJournal of Clinical Oncology
researchProduct

Sorafenib in combination with docetaxel as first-line therapy for HER2-negative metastatic breast cancer: Final results of the randomized, double-bli…

2019

Abstract Background This multicenter, double-blind phase II study assessed the antitumor activity and toxicity profile of docetaxel with the antiangiogenic multikinase inhibitor sorafenib or matching placebo as a first-line treatment in patients with metastatic or locally advanced HER2-negative breast cancer. Patients and methods Patients were randomized 1:1 to receive docetaxel 100 mg/m2 on day 1 every 3 weeks in combination with sorafenib 400 mg bid or placebo on days 2–18 of each cycle until tumor progression, or unacceptable toxicity. Sorafenib/placebo could be continued at the investigator's discretion if docetaxel was stopped due to toxicity. Primary endpoint was progression free surv…

OncologySorafenibAdultmedicine.medical_specialtyReceptor ErbB-2medicine.medical_treatmentPhases of clinical researchAngiogenesis InhibitorsBreast NeoplasmsDocetaxelurologic and male genital diseasesPlaceboDrug Administration Schedule03 medical and health sciences0302 clinical medicineDouble-Blind MethodInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumans030212 general & internal medicineProgression-free survivalneoplasmsAgedAged 80 and overChemotherapyTaxanebusiness.industryGeneral MedicineMiddle AgedSorafenibmedicine.diseaseMetastatic breast cancerProgression-Free SurvivalTreatment OutcomeDocetaxel030220 oncology & carcinogenesisSurgeryFemalebusinessmedicine.drugBreast (Edinburgh, Scotland)
researchProduct